文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

ASCENDE-RT 试验生存终点的更新分析

An Updated Analysis of the Survival Endpoints of ASCENDE-RT.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-12-15

ASCENDE-RT 试验将中危和高危前列腺癌患者随机分配至低剂量率近距离放疗增强(LDR-PB)或剂量递增外照射增强(DE-EBRT),在中位随访 10 年时更新主要终点和次要生存终点;LDR-PB 组至生化进展时间(TTP)优势持续存在,10 年 TTP 为 85%±5% 对 67%±7%(P<.001),总生存、远处转移和前列腺癌特异性死亡无显著差异。

要点

  • 10 年 TTP 估计值 LDR-PB 组为 85%±5%,DE-EBRT 组为 67%±7%(log rank P<.001)。
  • 10 年远处转移率 LDR-PB 组 88%±5%,DE-EBRT 组 86%±6%(P=.56),无显著差异。
  • 10 年总生存率 LDR-PB 组 80%±6%,DE-EBRT 组 75%±7%(P=.51),无显著差异。

核心结论

  • 随机分配至 LDR-PB 增强臂的男性相比 DE-EBRT 臂持续存在 TTP 的大幅优势。
  • ASCENDE-RT 的检验效能不足以检测次要生存终点(OS、DM 和前列腺癌特异性死亡时间)的差异,且未观察到明显差异。

研究设计与样本

  • 随机对照试验,按 1:1 随机分配至 LDR-PB 臂或 DE-EBRT 臂。
  • 全部患者接受 1 年雄激素剥夺治疗和 46 Gy/23 次盆腔放疗。
  • DE-EBRT 臂额外接受 32 Gy/16 次,LDR-PB 臂接受 125I 植入,处方最小周边剂量 115 Gy。
  • DE-EBRT 臂随机 200 例,LDR-PB 臂随机 198 例。

主要发现

  • 10 年 Kaplan-Meier TTP 估计值 LDR-PB 组为 85%±5%,DE-EBRT 组为 67%±7%(log rank P<.001)。
  • 10 年远处转移时间 LDR-PB 组为 88%±5%,DE-EBRT 组为 86%±6%(P=.56)。
  • 共有 117 例(29%)死亡,10 年 OS 估计值 LDR-PB 组为 80%±6%,DE-EBRT 组为 75%±7%(P=.51)。
  • 30 例(8%)患者死于前列腺癌:LDR-PB 组 12 例(6%),包括 2 例治疗相关死亡;DE-EBRT 组 18 例(9%)。

局限性

  • ASCENDE-RT 的检验效能不足以检测次要生存终点(OS、DM 和前列腺癌特异性死亡时间)的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Using the primary endpoint of time to biochemical progression (TTP), Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (ASCENDE-RT) randomized National Comprehensive Cancer Network patients with intermediate and high-risk prostate cancer to low-dose-rate brachytherapy boost (LDR-PB) or dose-escalated external beam boost (DE-EBRT). Randomization to the LDR-PB arm resulted in a 2-fold reduction in biochemical progression compared with the DE-EBRT group at a median follow-up of 6.5 years (P < .001). Herein, the primary endpoint and secondary survival endpoints of the ASCENDE-RT trial are updated at a 10-year median follow-up. METHODS: Patients were randomly assigned to either the LDR-PB or the DE-EBRT arm (1:1). All patients received 1 year of androgen deprivation therapy and 46 Gy in 23 fractions of pelvic RT. Patients in the DE-EBRT arm received an additional 32 Gy in 16 fractions, and those in the LDR-PB arm received an 125I implant prescribed to a minimum peripheral dose of 115 Gy. Two hundred patients were randomized to the DE-EBRT arm and 198 to the LDR-PB arm. RESULTS: The 10-year Kaplan-Meier TTP estimate was 85% ± 5% for LDR-PB compared with 67% ± 7% for DE-EBRT (log rank P < .001). Ten-year time to distant metastasis (DM) was 88% ± 5% for the LDR-PB arm and 86% ± 6% for the DE-EBRT arm (P = .56). There were 117 (29%) deaths. Ten-year overall survival (OS) estimates were 80% ± 6% for the LDR-PB arm and 75% ± 7% for the DE-EBRT arm (P = .51). There were 30 (8%) patients who died of prostate cancer: 12 (6%) in the LDR-PB arm, including 2 treatment-related deaths, and 18 (9%) in the DE-EBRT arm. CONCLUSIONS: Men randomized to the LDR-PB boost arm of the ASCENDE-RT trial continue to experience a large advantage in TTP compared with those randomized to the DE-EBRT arm. ASCENDE-RT was not powered to detect differences in its secondary survival endpoints (OS, DM, and time to prostate cancer-specific death) and none are apparent.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Oh J, Tyldesley S, Pai H, et al. An Updated Analysis of the Survival Endpoints of ASCENDE-RT. Int J Radiat Oncol Biol Phys. 2022. PMID: 36528488. doi:10.1016/j.ijrobp.2022.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。